Burns J W & Co. Inc. NY reduced its position in shares of iShares Nasdaq Biotechnology ETF (NASDAQ:IBB) by 0.7% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 26,940 shares of the financial services provider’s stock after selling 197 shares during the period. Burns J W & Co. Inc. NY’s holdings in iShares Nasdaq Biotechnology ETF were worth $2,681,000 at the end of the most recent quarter.
Several other hedge funds have also recently bought and sold shares of the company. JPMorgan Chase & Co. raised its holdings in iShares Nasdaq Biotechnology ETF by 120.0% during the second quarter. JPMorgan Chase & Co. now owns 1,108,069 shares of the financial services provider’s stock worth $118,874,000 after acquiring an additional 604,388 shares in the last quarter. Tibra Equities Europe Ltd bought a new stake in iShares Nasdaq Biotechnology ETF in the second quarter valued at approximately $58,914,000. Natixis raised its stake in iShares Nasdaq Biotechnology ETF by 66.7% in the second quarter. Natixis now owns 1,250,929 shares of the financial services provider’s stock valued at $136,476,000 after buying an additional 500,326 shares during the period. SG Americas Securities LLC bought a new stake in iShares Nasdaq Biotechnology ETF in the second quarter valued at approximately $16,695,000. Finally, Voloridge Investment Management LLC bought a new stake in iShares Nasdaq Biotechnology ETF in the second quarter valued at approximately $14,267,000. 77.35% of the stock is owned by institutional investors.
Separately, ValuEngine upgraded iShares Nasdaq Biotechnology ETF from a “hold” rating to a “buy” rating in a research note on Wednesday, October 2nd.
The business also recently declared a — dividend, which was paid on Monday, September 30th. Investors of record on Wednesday, September 25th were given a dividend of $0.0715 per share. This represents a yield of 0.1%. The ex-dividend date was Tuesday, September 24th.
iShares Nasdaq Biotechnology ETF Company Profile
iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.
Want to see what other hedge funds are holding IBB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for iShares Nasdaq Biotechnology ETF (NASDAQ:IBB).
Receive News & Ratings for iShares Nasdaq Biotechnology ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares Nasdaq Biotechnology ETF and related companies with MarketBeat.com's FREE daily email newsletter.